Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

2.

[Detection of minimal residual disease in children with neuroblastoma].

De Moerloose B, Swerts K.

Verh K Acad Geneeskd Belg. 2005;67(1):33-44. Review. Dutch.

PMID:
15828305
3.

Detection and treatment of minimal residual disease in high-risk neuroblastoma.

Reynolds CP.

Pediatr Transplant. 2004 Jun;8 Suppl 5:56-66. Review.

PMID:
15125707
4.

Targeted immunotherapy for high-risk neuroblastoma--the role of monoclonal antibodies.

Parsons K, Bernhardt B, Strickland B.

Ann Pharmacother. 2013 Feb;47(2):210-8. doi: 10.1345/aph.1R353. Epub 2013 Feb 5. Review.

PMID:
23386066
5.

Monoclonal antibodies and neuroblastoma.

Miraldi F.

Semin Nucl Med. 1989 Oct;19(4):282-94. Review.

PMID:
2678480
6.

Monoclonal antibody-based therapy for neuroblastoma.

Cheung NK.

Curr Oncol Rep. 2000 Nov;2(6):547-53. Review.

PMID:
11122891
7.

Evaluation of bone marrow as a metastatic site of human neuroblastoma.

Morandi F, Corrias MV, Pistoia V.

Ann N Y Acad Sci. 2015 Jan;1335:23-31. doi: 10.1111/nyas.12554. Epub 2014 Oct 14. Review.

PMID:
25315505
8.

Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma.

Mora J.

Expert Rev Clin Pharmacol. 2016;9(5):647-53. doi: 10.1586/17512433.2016.1160775. Epub 2016 Mar 21. Review.

PMID:
26934530
10.

Targeted radiotherapy and immunotherapy of human neuroblastoma with GD2 specific monoclonal antibodies.

Cheung NK, Munn D, Kushner BH, Usmani N, Yeh SD.

Int J Rad Appl Instrum B. 1989;16(2):111-20. Review. No abstract available.

PMID:
2497088
11.

Purging tumor cells from bone marrow by use of antibody and complement: a critical appraisal.

Gee AP, Boyle MD.

J Natl Cancer Inst. 1988 Apr 6;80(3):154-9. Review.

PMID:
3279217
12.

Contemporary therapeutic options for children with high risk neuroblastoma.

Sterba J.

Neoplasma. 2002;49(3):133-40. Review.

PMID:
12097996
13.

GD2-Targeted Immunotherapy and Potential Value of Circulating microRNAs in Neuroblastoma.

Gholamin S, Miezaei H, Razavi SM, Hassanian SM, Saadatpour L, Masoudifar A, ShahidSales S, Avan A.

J Cell Physiol. 2017 Feb 1. doi: 10.1002/jcp.25793. [Epub ahead of print] Review.

PMID:
28145567
14.

Monoclonal antibody therapy.

Schwartz MA, Scheinberg DA, Houghton AN.

Cancer Chemother Biol Response Modif. 1992;13:156-74. Review. No abstract available.

PMID:
1389908
15.

Recommendations for the standardization of bone marrow disease assessment and reporting in children with neuroblastoma on behalf of the International Neuroblastoma Response Criteria Bone Marrow Working Group.

Burchill SA, Beiske K, Shimada H, Ambros PF, Seeger R, Tytgat GA, Brock PR, Haber M, Park JR, Berthold F.

Cancer. 2017 Apr 1;123(7):1095-1105. doi: 10.1002/cncr.30380. Epub 2016 Dec 16. Review.

PMID:
27984660
16.

Glycobiology of neuroblastoma: impact on tumor behavior, prognosis, and therapeutic strategies.

Berois N, Osinaga E.

Front Oncol. 2014 May 23;4:114. doi: 10.3389/fonc.2014.00114. eCollection 2014. Review.

17.

[Exploration and analysis of PCR-inhibitory components in peripheral blood and bone marrow samples].

Shen KF, Yang M, Jiang QL.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Jun;22(3):842-6. doi: 10.7534/j.issn.1009-2137.2014.03.050. Review. Chinese.

PMID:
24989306

Supplemental Content

Support Center